LLY

Business Context and Reporting Period

Company: Eli Lilly and Company (LLY)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended March 31, 2026
Business Overview: Lilly operates as a single segment engaged in the discovery, development, manufacturing, and sales of pharmaceutical products worldwide. The company is a large accelerated filer with 941.7 million shares of common stock outstanding as of April 27, 2026.

Key Financial Metrics

Key Drivers: Revenue growth was driven primarily by volume increases in Mounjaro and Zepbound, partially offset by lower realized prices. Net income surged due to higher gross margins and a significant reduction in acquired in-process research and development (IPR&D) charges compared to the prior year.

Material Changes vs. Prior Period

• Revenue Composition: Incretin medicines (Mounjaro and Zepbound) accounted for 65% of total revenue in Q1 2026. Mounjaro revenue grew 125% year-over-year, while Zepbound grew 80%.
• Expense Reduction: Acquired IPR&D charges dropped to $584 million from $1.572 billion in Q1 2025, a decrease of 63%. The prior year's high charges were largely due to the Scorpion Therapeutics acquisition.
• Acquisitions: In March 2026, Lilly acquired Ventyx Biosciences for approximately $1.1 billion (net of cash) to expand its pipeline in inflammatory-mediated diseases.
• Tax Rate: The effective tax rate decreased to 16.4% from 20.2%, primarily due to the unfavorable tax impact of non-deductible IPR&D charges in the prior year.
• Share Repurchases: The company repurchased $2.3 billion of common stock in Q1 2026, leaving $8.6 billion remaining under its $15.0 billion program authorized in December 2024.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Pipeline: The FDA approved orforglipron (Foundayo) for obesity in April 2026. Phase 3 trials for retatrutide (Type 2 diabetes) and eloralintide (obesity, OSA, OA) have met endpoints or been initiated.
• Pricing & Policy: Lilly finalized voluntary agreements with the U.S. government to lower Medicaid prices and launch new medicines with balanced pricing. The Medicare GLP-1 Bridge Program will provide discounted access to obesity medicines starting July 1, 2026.
• IRA Impact: Jardiance is subject to government-set prices effective 2026; Trulicity and Verzenio are selected for 2028 pricing. Management expects other significant products to be selected in future years.
• Manufacturing: Significant capital expenditures are underway to expand manufacturing capacity to meet anticipated demand for incretin medicines.

Risks and Contingencies:

• Legal Proceedings: Ongoing litigation includes patent disputes (Emgality), product liability claims for incretin medicines (Mounjaro, Zepbound, Trulicity), and pricing investigations (340B program, insulin pricing).
• Regulatory: Risks include potential supply disruptions, regulatory actions regarding manufacturing quality, and the impact of global trade tariffs.
• Counterfeit Products: Continued production and sale of counterfeit and mass-compounded incretins pose patient safety risks and market challenges.

Investor Verification Checklist

• Revenue Sustainability: Verify the durability of volume growth for Mounjaro and Zepbound against potential price erosion from government negotiations and the Medicare Bridge Program.
• Acquisition Integration: Monitor the integration and pipeline progress of the newly acquired Ventyx Biosciences assets.
• Legal Exposure: Track developments in the Emgality patent appeal and the consolidated product liability MDLs regarding incretin medicines.
• Capital Allocation: Assess the balance between aggressive share repurchases ($2.3B in Q1) and the capital required for manufacturing expansion and future acquisitions (up to $12B in pending commitments).
• IRA Pricing Impact: Evaluate the financial impact of government-set pricing on Jardiance (2026) and future selections like Trulicity and Verzenio.